Cohere Health introduced a new tool for payers called Review Assist. It is meant to support health plan clinical staff with prior authorization reviews and other use cases.

Caris Life Sciences applies AI and machine learning to patient samples to detect cancer and as a companion diagnostic guiding the use of targeted cancer therapies. As a commercial-stage company, Caris’s upsized public markets debut is an outlier amid the continuing IPO freeze for clinical-stage biotechs developing new drugs.

Intermountain Health is deploying Layer Health’s AI engine for clinical data abstraction across several of its patient registries. The health system’s venture capital arm is also making a strategic investment in the startup.

To be clear, this doesn’t mean healthcare organizations should adopt LLMs tomorrow. But what’s changed is that the primary obstacle – cost at scale – is no longer the immovable obstacle it once was. For healthcare leaders who have been watching the AI wave from the sidelines, this is the moment to move from curiosity to action.

It’s a bold attempt to recalibrate global drug pricing — with U.S. patients at the center. But without clear enforcement, legal grounding, or international cooperation, its future remains very uncertain.

Just a year after its launch, Bluebird Kids Health is already announcing plans to double its number of pediatric clinics. The startup seeks to improve pediatric care access in underserved areas by building practices in these neighborhoods and accepting all insurance types.

Draig Therapeutics’ lead drug is designed to safely target the AMPA receptor as a way of mediating the interplay between two neurotransmitters whose imbalance is associated with mood disorders. The startup is one of several that have recently raised mega rounds of financing to support programs in the clinic or entering clinical testing.